Procter & Gamble Hygiene and Health Care Limited Intrinsic Value
PGHH · Fast Moving Consumer Goods · Current price ₹7,170.5
Is Procter & Gamble Hygiene and Health Care Limited undervalued?
We estimate the fair value of Procter & Gamble Hygiene and Health Care Limited at ₹2,450 per share, against a market price of ₹7,518. That puts the share price about -67.4% above our estimate, at medium confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.
How this fair value is calculated
This estimate comes from 2 methods: Discounted cash flow (2-stage) (₹2,603), PEG (growth-implied P/E) (₹1,973). Each is weighted by how well its inputs held up for this company. The full working, including the assumptions and what data was missing, is set out below.
The range around this estimate
Our estimate for Procter & Gamble Hygiene and Health Care Limited spans ₹1,973 to ₹2,695. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.
Margin of safety
Value investors look for a margin of safety: a discount to estimated value that absorbs being wrong. At ₹7,518 against an estimated value of ₹2,450, Procter & Gamble Hygiene and Health Care Limited trades at -67.4%, i.e. a premium to our estimate. How much margin to demand depends on how much you trust the inputs, which is what the confidence band below is for.
How we got this fair value
Every number below is part of the same estimate for Procter & Gamble Hygiene and Health Care Limited. Nothing here is a target price or a forecast of where the share price will go.
Workable, with real gaps. Weigh it alongside your own view rather than on its own.
Estimate range ₹1,973 – ₹2,695
Why this method for this business
DCF and PEG are the most appropriate models for an asset-light, branded consumer franchise with durable moats and predictable earnings power.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
Intrinsic value from 2-stage discounted cash flows (primary for asset-light / normal businesses); FCFE path
- relative_pe is rejected due to its outlier status and inapplicability for a high-quality FMCG business
What was missing
- Lack of forward-looking analyst estimates for more precise growth assumptions
What drives it
15 inputs, grouped by how strong each claim is
- FCF_0 (normalized)
- 544 ₹cr
- Net debt
- 0.9 ₹cr
- Earnings growth
- 8.1% CAGR
- EPS (TTM)
- 243.59 ₹/share
fcf_norm (median ≤5y positive)
gross debt (cash n/a)
computed
computed
- Discount rate (r)
- 12.9%
- Beta
- 0.8
COE (building-block)
bottom-up industry
- Stage-1 start growth
- 5.61%
- Fade shape
- gentle
- Terminal growth (g)
- 5.5%
- Stage-1 years
- 14 y
pat_cagr_5y
lifecycle Cash-Cow
macro terminal × quality premium
lifecycle Cash-Cow horizon
- Lifecycle stage
- Cash-Cow
- Quality premium
- 1.1×
forecast engine (L20)
moat Wide + capital allocation
- Path
- FCFE
- Terminal-value fraction
- 0.388
- Growth-implied P/E
- 8.1×
computed (D/E vs 0.8)
PV_TV / (PV_1+PV_TV)
min(growth, 30)
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for Procter & Gamble Hygiene and Health Care Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyMore on Procter & Gamble Hygiene and Health Care Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.